MBX-2982

Overview

MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Endocrinology and Metabolic Disease | GPR119

Product Information

• Catalog No.: B0084-456604
• CAS No.: 1037792-44-1
• Molecular Formula: C22H24N8OS
• Molecular Weight: 448.549
• Purity: 98%

Source

Original product source